Amgen to develop next-generation biomanufacturing plant in US

Pharmaceutical Company Restructures

Amgen has announced that it will be building a state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, Rhode Island.

The facility will be the first of its kind in the US and will utilise Amgen's biomanufacturing capabilities to create new products for the US and global markets. It is expected to create around 150 new highly-skilled manufacturing positions, plus approximately 200 construction and validation jobs.

“Amgen has announced plans to create a next-generation biomanufacturing plant in Rhode Island.“

Multiple innovative technologies will be deployed within the facility, meaning it can be built in half the construction time and at approximately half of the operating cost of a traditional plant. It will also have a smaller manufacturing footprint and offer greater environmental benefits.

Amgen opened its first next-generation biomanufacturing plant in Singapore in 2014, making use of a flexible, modular design that can be replicated in future facilities such as this one. This allows Amgen to respond rapidly to evolving demands, improving the speed at which a medicine can be made available for patients.

Esteban Santos, executive vice-president of operations at Amgen, said: "Amgen has three decades of experience in biologics manufacturing, and we are proud of our track record of providing a reliable supply of high-quality medicines for patients around the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news